Background {#Sec1}
==========

Hemodynamic shock is a leading cause of morbidity and mortality in the pediatric population worldwide \[[@CR1]\]. A delay in treating shock may result in irreversible organ damage \[[@CR2], [@CR3]\]. Morbidity from shock may include renal failure, disseminated intravascular coagulation (DIC), and death \[[@CR1]--[@CR3]\]. Early goal-directed therapy is targeted at maintaining and restoring an adequate ventilation and circulation within the first hour of shock onset \[[@CR4]--[@CR6]\].

Aggressive fluid resuscitation is the first line of therapy for shock \[[@CR7]\]. Thereafter, hemodynamic support is achieved with vasopressors and inotropes \[[@CR5], [@CR7]\]. However, reduced vasoconstrictor sensitivity to vasopressors in shock can lead to vasodilation, severe hypotension, and vasoparalysis \[[@CR8]\]. There is, therefore, a pressing need for agents which target other pathways involved in the development of shock.

In the past decade, arginine-vasopressin (AVP) has emerged as a potentially useful therapy for refractory shock \[[@CR9]\]. AVP acts on V1 receptors located on vascular smooth muscle leading to an increase in mean arterial pressure (MAP). Patients with shock exhibit inappropriately low circulating AVP concentrations \[[@CR7], [@CR8], [@CR10]\]. From a biologic perspective, the basic rationale behind the addition of AVP/TP in refractory shock is the depletion of endovascular AVP in states of shock \[[@CR11]\]. Furthermore, AVP/terlipressin (TP) may contribute to MAP elevation in the refractory shock state since vascular smooth muscle shows a decreased ability to contract, and the hypotension may be refractory to standard catecholamine vasopressor therapy \[[@CR12]\].

AVP and TP administration in states of shock may be beneficial in improving cardiovascular parameters, such as MAP and heart rate (HR) \[[@CR13], [@CR14]\]. AVP/TP may also be used in vasodilatory shock following cardiopulmonary bypass \[[@CR15]\].

There is a paucity of data regarding the outcomes of the use of AVP/TP in refractory shock in children. A Cochrane review from 2013, which aimed to assess the efficacy and safety of AVP in neonates with refractory shock, did not find sufficient evidence to recommend or refute the use of AVP \[[@CR16]\]. We therefore sought to conduct a systematic review, meta-analysis, and trial sequential analysis (TSA) to evaluate the efficacy and safety of AVP/TP in critically ill neonates and children with refractory shock of different origins compared to conventional therapy with fluid resuscitation, vasopressor, and inotropic therapy.

Methods {#Sec2}
=======

Data sources and searches {#Sec3}
-------------------------

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA 2009) framework guidelines and the review protocol was registered at the PROSPERO registry of systematic reviews on February 2016 (registry number: CRD 42016035872) \[[@CR17], [@CR18]\]. The systematic review was performed using MEDLINE, EMBASE, and Cochrane through February 2016 to identify all published randomized controlled trials (RCTs), prospective clinical trials ("before and after", without a comparator group), cohort studies, case-control studies, and case series involving the treatment/comparison of AVP or TP (in addition to conventional therapy) in pediatric refractory shock (of septic, vasodilatory, or mixed origin) to conventional therapy. Relevant studies were identified using the following search terms: "vasopressin", "terlipressin", "shock", "septic", "refractory", "hypotension", "vasodilatory", "mixed", "children", "neonates". We subsequently searched and evaluated published systematic reviews, online resources, conference abstracts, clinicaltrials.gov, and expert opinion to ensure identification of all published and unpublished studies. No language or date restrictions were applied to the search. No approval from the Institutional Review Board was required.

Study selection and data extraction {#Sec4}
-----------------------------------

The studies were identified through a search by one reviewer (RM), and the abstracts were independently screened by two reviewers (RM and BHR). Disagreements were resolved by consensus and/or referral to a third reviewer (IM). The full text of the resulting references was then retrieved by one reviewer (RM). The primary endpoints of this analysis were mortality outcomes (30-day mortality in RCTs or mortality during/by end of trial in non-RCTs) and tissue ischemia (new onset or worsening of existing condition). Secondary outcomes included hemodynamic indices, vasoactive score, and the length of stay in the pediatric intensive care unit (PICU).

Selection criteria {#Sec5}
------------------

We applied the following screening criteria to determine qualitative eligibility for inclusion in the meta-analysis: prospective clinical studies (RCTs and prospective "before and after " clinical trials, without comparator group) of children aged 0 to 18 years and in refractory shock, which compared AVP/TP (in addition to conventional therapy) to conventional therapy and reported on mortality, morbidity, at least two hemodynamic indices, and adverse effects, and which met 1b and 1c levels of evidence of the Oxford Centre for Evidence-based Medicine (CEBM) levels of evidence 2011 \[[@CR19]\]. We excluded studies of AVP/TP for other indications, or with no full-text access. Retrospective and prospective observational studies and case reports were included in the systematic review only.

Quality assessment and risk of bias {#Sec6}
-----------------------------------

The methodological quality of the studies included was assessed using the CEBM levels of evidence 2011 \[[@CR19]\]. Risk of bias was assessed according to the Cochrane Collaboration methodology \[[@CR20]\].

Data synthesis {#Sec7}
--------------

We conducted a meta-analysis to pool the results of trials comparing conventional therapy only with conventional therapy plus AVP/TP using Comprehensive Meta-analysis (CMA 3.0). For TSA, the TSA program v.0.9 beta was used (<http://www.ctu.dk/tsa/downloads.aspx>). For bias risk assessment we used Review Manager (RevMan), Version 5.3. Copenhagen (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The primary comparison themes were mortality and tissue ischemia. Secondary comparison themes included vasoactive score, the length of stay in the PICU, and hemodynamic measures. For studies reporting only the interquartile range (IQR) for continuous measure outcomes, we assumed that the mean and median were equal, and calculated the standard deviation (SD) from IQR by dividing the IQR by 1.35 \[[@CR21]\]. To calculate the change in continuous hemodynamic measures we estimated the standard deviation from the pooled variance of each measure. Heterogeneity was assessed using the *I* ^2^ statistic. Values of 25%, 50%, and 75% for *I* ^2^ represented low, medium, and high heterogeneity, respectively \[[@CR22]\]. We used random-effects models to pool results. We calculated risk ratios (RRs) for dichotomous outcomes when including only RCTs in the analysis. Event rates (ERs) were calculated for dichotomous outcomes including RCTs and "before-and-after clinical" trials (without comparator). Event rates are a measure of how often an event occurred in a group \[[@CR23]\], and are measures of the occurrence of an event for each participant over the time they were observed. Pooled event rates from the \"before and after\" clinical trials can provide an estimate of the expected rates of these events in the settings evaluated; however, they do not provide a direct estimate of the relative effect of the intervention compared to a control. The mean difference (MD) was calculated for continuous outcomes, with their corresponding 95% confidence intervals (CIs). Statistical significance was defined using a two-sided α of 0.05, and interpretations of clinical significance emphasized CIs.

Trial sequential analysis {#Sec8}
-------------------------

Meta-analyses may result in type I errors owing to an increased risk of random error when sparse data are analyzed \[[@CR24]\]. TSA allows for controlling the *p* value when scarce data exist and clear conclusions cannot be drawn \[[@CR25], [@CR26]\]. TSA allows the quantification of the required sample size for determining the effect under study while adjusting the threshold for statistical significance \[[@CR25], [@CR26]\]. The threshold for reaching statistical significance adjusts the CIs and reduces type I errors. When the cumulative z-curve crosses the threshold boundaries, one may conclude that a sufficient level of evidence for the intervention effect has been reached and no further trials are needed. If the z-curve does not cross any of the boundaries, evidence to reach a conclusion is insufficient \[[@CR25]\]. We used TSA adjusted random-effects models to pool results from RCTs for primary outcomes. We conducted two- and one-sided TSA to maintain a risk of 5% for type I error and a power of 80%. We used the estimated function to calculate the required information size (IS). We calculated 95% CIs adjusted for repetitive testing.

Results {#Sec9}
=======

Trial flow {#Sec10}
----------

Our search yielded 140 relevant titles. Initial screening led to the exclusion of 18 duplicate records and 72 records that did not meet inclusion criteria. The remaining 50 publications were retrieved for full-text review. Twenty-two publications were excluded based on inclusion criteria, leaving 28 studies. Twenty studies were observational and were included in the systematic review only (Additional file [1](#MOESM1){ref-type="media"}: Table S1), leaving eight clinical publications for meta-analysis. The selection process is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Publication selection and search process

Characteristics and quality of clinical studies included in the meta-analysis {#Sec11}
-----------------------------------------------------------------------------

The studies included in the analysis are detailed in Table [1](#Tab1){ref-type="table"}. In total, 224 children received AVP/TP. In all reports, conventional therapy with volume resuscitation and vasopressors/inotropes were given prior to the initiation of AVP/TP (excluding one study which included volume resuscitation or dopamine) \[[@CR27]\]. Three RCTs \[[@CR27]--[@CR29]\] and five clinical trials \[[@CR30]--[@CR34]\] met the 1b and 1c level criteria of the CEBM \[[@CR19]\], and two RCTs had a low risk for bias (Additional file [2](#MOESM2){ref-type="media"}: Figure S1) \[[@CR27], [@CR29]\]. The studies included evaluated the effect of AVP/TP in the pediatric population over a relatively wide range of ages, and the majority of the studies were not restricted to shock arising from a specific mechanism.Table 1Published RCTs and clinical trials on the use of vasopressors in neonates and children sorted by study design (quality of evidence)Author, yearStudy designType of shock/indication for AVP/TP administrationAgeNumber of subjects by treatment receivedTreatment (medication, dose, duration)OutcomesAdverse eventsStudy periodOxford levels of evidence 2011Choong et al., 2009 \[[@CR29]\]Randomized controlled double-blind trial (RCT)Vasodilatory1 month to 17 years69 children: 35, AVP; 34, placeboIV AVP continuous infusion: 0.0005--0.002 units/kg/minMortality: AVP, 10/33; placebo, 5/32; *p* = 0.21 MAP: AVP, increase; placebo, increase; *p* = 0.02 HR: NA UO: AVP, decrease; placebo, decrease; *p* = 0.65 Catecholamine requirement: AVP, unchanged; placebo, unchanged; *p* = 0.93 Vasoactive score: AVP,: unchanged; control, unchanged; *p* = 0.93New onset tachycardia: 0 Tissue ischemia/skin lesions: AVP, 2; placebo, 0; *p* = 0.15 Cardiac arrest: AVP, 1; placebo, 0; *p* = 0.55 Rhabdomyolysis: 0 Metabolic acidosis: 04 years1bRios and Kaiser, 2015 \[[@CR27]\]Randomized controlled double-blind trial (RCT)Refractory hypotension\<24 h (mean age: 6.5 h)70 ELBW infants: 10, AVP; 10, dopamine; 50, controlIV AVP continuous infusion: 0.0001--0.0006 units/kg/minMortality: AVP, 1/10; dopamine, 1/10; control, 0/50; *p* = 0.261 MAP: AVP, increase (9/10); dopamine, increase (8/10); control, NA; *p* = 1.0 HR: AVP, unchanged; dopamine, increase; control, NA; *p* \< 0.01 UO: AVP, unchanged; dopamine, unchanged; control, unchanged; *p* = 0.384 Catecholamine requirement: AVP, unchanged; placebo, unchanged; *p* = 0.93 Vasoactive score: NANew onset tachycardia: 0 Tissue ischemia/skin lesions: AVP, 0: dopamine, 1; control, 2; *p* = 0.15 Cardiac arrest: AVP, 1; placebo, 0; *p* = 0.801 Rhabdomyolysis: NA Metabolic acidosis: NA2 years1bYildizdas et al., 2008 \[[@CR28]\]Clinical, non-blind, controlled trial,Septic1 month to 5.5 years58 children: 30, TP; 28, controlIV TP bolus: 20 μg/kg every 6 hMortality: TP, 20/30; control, 20/28; *p* = 0.1 MAP: TP, increase; *p* = 0.001; control, NA HR: TP, decrease, *p* = 0.001, control, NA UO: TP, unchanged;, control, unchanged; *p* = 0.2 Catecholamine requirement: NA Vasoactive score: NANew onset tachycardia: 0 Tissue ischemia/skin lesions: TP, 5; control, 3; *p* = 0.3 Cardiac arrest: 0 Rhabdomyolysis: 0 Metabolic acidosis: 06 months1bAgrawal et al., 2012 \[[@CR30]\]Clinical trialVasodilatory (post-cardiac surgery)1 month to 8.5 years12 childrenIV AVP continuous infusion: 0.0005--0.03 units/kg/minMortality: 3/12 Morbidity: NA MAP: increase; *p* \< 0.001 HR: unchanged; *p* = 0.188 UO: NA Catecholamine requirement: decrease; *p* \< 0.001 Vasoactive score: after AVP, decrease; *p* = 0.001New onset tachycardia: 0 Tissue ischemia/skin lesions: 0 Cardiac arrest: 0 Rhabdomyolysis: 0 Metabolic acidosis: 06 months1cRodriguez-Núñez et al., 2010 \[[@CR31]\]Clinical trialSeptic24 days to 15 years15 childrenIV TP loading dose: 20 μg/kg continuous infusion: 4--20 μg/kg/hMortality: 7/15 Morbidity: NA MAP: increase; *p* \< 0.05 HR: decrease; *p* \< 0.05 UO: NA Catecholamine requirement: decrease, *p* \< 0.05New onset tachycardia: 0 Tissue ischemia/skin lesions: 4 Cardiac arrest: 1 Rhabdomyolysis: 4 Metabolic acidosis: 332 months1cRodriguez-Núñez et al., 2006 \[[@CR32]\]Clinical trialSeptic1 month to 13 years16 childrenIV TP bolus: 0.02 mg/kg every 4 h, for a maximum of 17 hMortality: 9/16 Morbidity: NA MAP: increase; *p* \< 0.01 HR: unchanged; *p* = not significant UO: NA Catecholamine requirement: decrease; *p* \< 0.05 Vasoactive score: after AVP, decrease; *p* \< 0.05New onset tachycardia: 0 Tissue ischemia/skin lesions: 5 Cardiac arrest: 0 Rhabdomyolysis: 2 Metabolic acidosis: 012 months1cBidegain et al., 2010 \[[@CR34]\]Observational-retrospectiveRefractory hypotension/septic1 day to 8 months20 childrenIV AVP continuous infusion: 0.00017--0.0007 units/kg/minMortality: 13/20 Morbidity: NA MAP: increase; *p* = 0.002 HR: decrease; *p* = 0.45 UO: decrease; *p* = 0.36 Catecholamine requirement: decrease; dopamine, *p* = 0.006; epinephrine, *p* = 0.04New onset tachycardia: 0 Tissue ischemia/skin lesions: 0 Cardiac arrest: 0 Rhabdomyolysis: 0 Metabolic acidosis: 02.5 years1cMatok et al., 2005 \[[@CR33]\]Observational-retrospectiveSeptic4 days to 17.7 years14 childrenIV TP: loading dose: 7 μg/kg/dose, twice daily maintenance: 20 μg/kg every 6 hMortality: 8/14 Morbidity: NA MAP: increase; *p* = 0.001 HR: decrease; *p* = 0.003 UO: increase, *p* = 0.011 Catecholamine requirement: decrease, 8/14; *p* = NANew onset tachycardia: 0 Tissue ischemia/skin lesions: 0 Cardiac arrest: 0 Rhabdomyolysis: 0 Metabolic acidosis: 01 year1cThe studies in Table [1](#Tab1){ref-type="table"} were included in the meta-analysisMortality-refers to pediatric/neonatal intensive care unit mortality*AVP* arginine-vasopressin, *ELBW* extremely low birth weight, *HR* heart rate, *IV* intravenous, *MAP* mean arterial pressure, *NA* not available, *TP* terlipressin, *UO* urine output

Meta-analysis {#Sec12}
-------------

### Mortality {#Sec13}

The addition of AVP/TP to vasopressor/inotropic therapy in refractory shock had no significant effect on mortality. Analysis of RCTs resulted in a non-significant difference in risk compared to conventional treatment, with a RR of 1.19 with low heterogeneity (95% CI, 0.71--2.00; *I* ^2^ = 28%) (Fig. [2](#Fig2){ref-type="fig"}). The mortality rate among patients treated with AVP/TP in the clinical trials was high, with a pooled ER of 0.49 (95% CI, 0.37--0.61) (Fig. [3](#Fig3){ref-type="fig"}). In TSA, the boundary for futility was not crossed, and no effect on mortality was observed; the estimated IS to reach the futility boundaries was 392 randomized patients (Fig. [4](#Fig4){ref-type="fig"}).Fig. 2The risk ratio for mortality in randomized controlled trials (*RCTs*). The forest plot demonstrates point estimates of risk ratio surrounded by 95% confidence interval (*CI*). *AVP* arginine-vasopressin, *TP* terlipressin Fig. 3Event rate for mortality in all clinical trials. The plot demonstrates point estimates of event rates surrounded by 95% confidence interval (*CI*). *ER* event rate Fig. 4Trial sequential analysis for mortality in randomized controlled trials: a relative risk of 1.01, two-sided boundary, incidence of 14.2% in the control arm, incidence of 25.5% in the treatment arm, a low bias estimated relative risk reduction of 80%, α of 5%, power of 80% were set. There is an estimated required information size of 392 randomized patients that are not reached. The boundaries for futility are not crossed and no effect on mortality is observed; the z-curve is parallel to the boundary of the treatment group. *AVP* arginine-vasopressin, *TP* terlipressin

### Tissue ischemia {#Sec14}

The addition of AVP/TP to vasopressor/inotropic therapy in refractory shock had no significant effect on the risk for developing tissue ischemia. Analysis of RCTs resulted in a non-significant difference in risk compared to conventional treatment, with a RR of 1.48 with low heterogeneity (95% CI, 0.47--4.62; *I* ^2^ = 0%) (Fig. [5](#Fig5){ref-type="fig"}). The tissue ischemia rate among patients treated with AVP/TP in the clinical trials was considerable, with a pooled ER of 0.16 (95% CI, 0.08--0.28) (Additional file [3](#MOESM3){ref-type="media"}: Figure S2). In TSA, the boundary for futility was not crossed, and no effect on tissue ischemia was observed; the estimated IS to reach the futility boundaries was 231 randomized patients (Additional file [4](#MOESM4){ref-type="media"}: Figure S3).Fig. 5The risk ratio for tissue ischemia in randomized controlled trials (*RCTs*). The forest plot demonstrates point estimates of risk ratio surrounded by 95% confidence interval (*CI*). *AVP* arginine-vasopressin, *TP* terlipressin

### Vasoactive score {#Sec15}

The addition of AVP/TP in refractory shock resulted in a significant decrease in the vasoactive score compared to standard therapy, with a pooled MD of --14.13 units and low heterogeneity (95% CI, --20.61 to --7.66; *I* ^2^ = 38.25%) (Additional file [5](#MOESM5){ref-type="media"}: Figure S4).

### Mean arterial pressure {#Sec16}

The addition of AVP/TP in refractory shock resulted in a significant increase in the MAP, with a pooled MD of 12.34 mmHg and high heterogeneity (95% CI, 6.38--18.3; *I* ^2^ = 93%) (Additional file [6](#MOESM6){ref-type="media"}: Figure S5).

### Heart rate {#Sec17}

The addition of AVP/TP in refractory shock resulted in a significant decrease in the HR, with a pooled MD of --12.25 beats per minute and intermediate heterogeneity (95% CI, --18.96 to --5.55; *I* ^2^ = 67%) (Additional file [7](#MOESM7){ref-type="media"}: Figure S6).

### Length of stay in the PICU {#Sec18}

The addition of AVP/TP in refractory shock did not result in a significant decrease in the length of stay, with a pooled MD of --3.58 days (reduction) and intermediate heterogeneity (95% CI, --9.05 to 1.83; *I* ^2^ = 54%) (Additional file [8](#MOESM8){ref-type="media"}: Figure S7).

Discussion {#Sec19}
==========

In this meta-analysis, no significant difference in mortality risk was found between AVP/TP and conventional treatment for refractory shock in the pediatric population. Furthermore, after applying TSA, the non-significant effect on mortality outcomes remained; however, a large number of randomized patients would be required to reach the futility boundary. Although no significant difference in tissue ischemia risk was found, when applying TSA we found a trend towards a higher risk for tissue ischemia.

AVP/TP treatment did significantly improve hemodynamic indices, with a significant reduction in the vasoactive score, HR, and an increase in MAP.

Our meta-analysis indicates that AVP/TP therapy is ineffective in reducing mortality in refractory shock in the pediatric population. Our results demonstrate that mortality rates among patients treated with AVP/TP in the clinical trials were high, as evidenced by the pooled ER estimate for mortality. Moreover, analysis of RCTs resulted in a non-significant difference in the relative risk for death between the treatment and control groups. The high mortality rates in the studies included in our analysis can be attributed to the high risk for mortality characteristic of refractory shock despite proper treatment \[[@CR4]\]. However, our results indicate that a very large number of patients would be necessary to reach the information size required to reach the futility boundaries for mortality, as shown by TSA.

AVP acts on V1 receptors located on vascular smooth muscle leading to vasoconstriction, and therefore therapy with AVP/TP may put the patients at a higher risk for developing tissue ischemia \[[@CR9]\]. In adults, RCTs showed a trend towards developing tissue ischemia with AVP/TP therapy \[[@CR35], [@CR36]\]. Our meta-analysis found high event rates for tissue ischemia among AVP/TP-treated patients.

The vasoactive score has previously been shown to be associated with morbidity and mortality in PICUs \[[@CR37], [@CR38]\], and also has been associated with improvement in length of stay in the PICU \[[@CR38]\]. Although AVP/TP treatment resulted in lower vasoactive scores, it did not significantly reduce clinically important outcomes such as mortality and the length of stay in the PICU.

Our analysis found a significant increase in MAP and a decrease in HR, in line with previous reports. These effects may be attributed to the mechanism by which AVP/TP causes vasoconstriction, and to the decreased sensitivity of vascular smooth muscle to catecholamines in refractory shock \[[@CR37]--[@CR39]\]. However, this did not seem to translate into a meaningful improvement in clinically significant outcomes.

Unfortunately, most of the studies included in our meta-analysis did not address the mechanism of shock and did not report on performing echocardiography during the study period, and, consequently, may have included patients with different mechanisms of shock. In light of the absence of information regarding ventricular function in most of the studies identified, and the fact that the outcome of neonatal and pediatric shock relies on ventricular function, we were unable to assess the relationship between the mechanism of shock and goal of treatment and the effectiveness of AVP/TP. As AVP and TP do not possess inotropic properties they are far less likely to be of use in states of shock where ventricular dysfunction is present. Additionally, the meta-analysis included studies with children of different ages. As scarce high-quality literature exists regarding the use of AVP/TP in neonates and children with refractory shock, a separate statistical analysis for neonates and children was not feasible. Our results are therefore limited by the nature of the available studies, as there may be difference between neonates and older children, and between different types of shock, regarding the mechanism of shock compensation and drug doses, as well as the potential for adverse effects. For example, the presence of DIC in refractory shock is probably higher than less severe types of shock, and AVP/TP is more likely to provide benefit in vasodilatory shock compared to cardiogenic shock \[[@CR40]\].

Conclusion {#Sec20}
==========

The results of our analysis emphasize the lack of observed benefit for AVP/TP in terms of mortality, as well as a possible association with ischemic events. While the data available on this topic are limited, and the possibility of a small benefit cannot be ruled out, our trial sequential analysis suggests that further studies are unlikely to demonstrate an improvement in mortality; however, more studies would be necessary to demonstrate this conclusively. Additionally, further studies of AVP/TP incorporating an evaluation of the mechanism of shock could enhance our understanding of the clinical utility of AVP/TP for specific types of shock.

We believe these findings are quite important, as they can both inform current practitioners as to the best available evidence regarding the efficacy and safety of these agents.
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